Xiao Li, Cheng Jiang, Yuwen Su, Ruiyun Gao, Peijun Yang, Yuechen Qin, Yue Zou, Weiming Liang, Jieru Quan, Liying Pan
{"title":"vonoprazan-阿莫西林双重治疗与含铋四联治疗对幽门螺杆菌感染患者的疗效和安全性：一项meta分析","authors":"Xiao Li, Cheng Jiang, Yuwen Su, Ruiyun Gao, Peijun Yang, Yuechen Qin, Yue Zou, Weiming Liang, Jieru Quan, Liying Pan","doi":"10.3389/fmicb.2025.1561749","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This meta-analysis aims to compare the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy in comparison to bismuth-containing quadruple therapy (BQT) for patients with <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection.</p><p><strong>Materials and methods: </strong>Four databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched published from establishment of database to June 1, 2024, for articles studying VA dual therapy compared to BQT for patients with <i>H. pylori</i> infection. Meta-analyses of eradication rates, adverse events, compliance and cost were preformed.</p><p><strong>Results: </strong>A total of 17 studies were included for meta-analysis. Compared with BQT, VA increased the incidence of <i>H. pylori</i> eradication rate, with significant difference under the ITT analysis (86.9% vs. 80.4%, RR = 1.07, 95% CI: 1.01-1.12, <i>p</i> = 0.01) but there no significant difference under the PP analysis (90.7% vs. 86.5%, RR = 1.03, 95% CI: 0.99-1.08, <i>p</i> = 0.13). Besides, VA significantly increased compliance (RR = 1.03, 95% CI: 1.01-1.05, <i>p</i> < 0.01) and decreased the occurrence of total adverse events (27.0% vs. 11.5%, RR = 0.43, 95% CI: 0.37-0.51, <i>p</i> < 0.01). Furthermore, VA has lower cost compared to BQT.</p><p><strong>Conclusion: </strong>Our findings indicated that VA dual therapy provided a higher eradication rate, enhanced compliance, decreased adverse events, and lowered cost relative to BQT for patients with <i>H. pylori</i> infection.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024576738, identifier CRD42024576738 (PROSPERO).</p>","PeriodicalId":12466,"journal":{"name":"Frontiers in Microbiology","volume":"16 ","pages":"1561749"},"PeriodicalIF":4.0000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962034/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with <i>Helicobacter pylori</i> infection: a meta-analysis.\",\"authors\":\"Xiao Li, Cheng Jiang, Yuwen Su, Ruiyun Gao, Peijun Yang, Yuechen Qin, Yue Zou, Weiming Liang, Jieru Quan, Liying Pan\",\"doi\":\"10.3389/fmicb.2025.1561749\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This meta-analysis aims to compare the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy in comparison to bismuth-containing quadruple therapy (BQT) for patients with <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection.</p><p><strong>Materials and methods: </strong>Four databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched published from establishment of database to June 1, 2024, for articles studying VA dual therapy compared to BQT for patients with <i>H. pylori</i> infection. Meta-analyses of eradication rates, adverse events, compliance and cost were preformed.</p><p><strong>Results: </strong>A total of 17 studies were included for meta-analysis. Compared with BQT, VA increased the incidence of <i>H. pylori</i> eradication rate, with significant difference under the ITT analysis (86.9% vs. 80.4%, RR = 1.07, 95% CI: 1.01-1.12, <i>p</i> = 0.01) but there no significant difference under the PP analysis (90.7% vs. 86.5%, RR = 1.03, 95% CI: 0.99-1.08, <i>p</i> = 0.13). Besides, VA significantly increased compliance (RR = 1.03, 95% CI: 1.01-1.05, <i>p</i> < 0.01) and decreased the occurrence of total adverse events (27.0% vs. 11.5%, RR = 0.43, 95% CI: 0.37-0.51, <i>p</i> < 0.01). Furthermore, VA has lower cost compared to BQT.</p><p><strong>Conclusion: </strong>Our findings indicated that VA dual therapy provided a higher eradication rate, enhanced compliance, decreased adverse events, and lowered cost relative to BQT for patients with <i>H. pylori</i> infection.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024576738, identifier CRD42024576738 (PROSPERO).</p>\",\"PeriodicalId\":12466,\"journal\":{\"name\":\"Frontiers in Microbiology\",\"volume\":\"16 \",\"pages\":\"1561749\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962034/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Microbiology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.3389/fmicb.2025.1561749\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3389/fmicb.2025.1561749","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
本荟萃分析旨在比较vonoprazan-amoxicillin （VA）双重治疗与含铋四联治疗（BQT）对幽门螺杆菌（H. pylori）感染患者的疗效和安全性。材料与方法：检索自建库至2024年6月1日出版的PubMed、Embase、Web of Science和Cochrane Library四个数据库，检索有关幽门螺旋杆菌感染患者的VA双重治疗与BQT比较的文章。对根除率、不良事件、依从性和成本进行meta分析。结果：共纳入17项研究进行meta分析。与BQT相比，VA增加了幽门螺杆菌根除率的发生率，ITT分析下差异有统计学意义（86.9%比80.4%,RR = 1.07,95% CI: 1.01-1.12, p = 0.01），PP分析下差异无统计学意义（90.7%比86.5%,RR = 1.03,95% CI: 0.99-1.08, p = 0.13）。此外，VA显著提高了幽门螺杆菌感染患者的依从性（RR = 1.03,95% CI: 1.01-1.05, p p ）。结论：我们的研究结果表明，相对于BQT， VA双重治疗可提高幽门螺杆菌感染患者的根除率，增强依从性，减少不良事件，降低成本。系统评价注册：https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024576738，标识符CRD42024576738 （PROSPERO）。
Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis.
Introduction: This meta-analysis aims to compare the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy in comparison to bismuth-containing quadruple therapy (BQT) for patients with Helicobacter pylori (H. pylori) infection.
Materials and methods: Four databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched published from establishment of database to June 1, 2024, for articles studying VA dual therapy compared to BQT for patients with H. pylori infection. Meta-analyses of eradication rates, adverse events, compliance and cost were preformed.
Results: A total of 17 studies were included for meta-analysis. Compared with BQT, VA increased the incidence of H. pylori eradication rate, with significant difference under the ITT analysis (86.9% vs. 80.4%, RR = 1.07, 95% CI: 1.01-1.12, p = 0.01) but there no significant difference under the PP analysis (90.7% vs. 86.5%, RR = 1.03, 95% CI: 0.99-1.08, p = 0.13). Besides, VA significantly increased compliance (RR = 1.03, 95% CI: 1.01-1.05, p < 0.01) and decreased the occurrence of total adverse events (27.0% vs. 11.5%, RR = 0.43, 95% CI: 0.37-0.51, p < 0.01). Furthermore, VA has lower cost compared to BQT.
Conclusion: Our findings indicated that VA dual therapy provided a higher eradication rate, enhanced compliance, decreased adverse events, and lowered cost relative to BQT for patients with H. pylori infection.
期刊介绍：
Frontiers in Microbiology is a leading journal in its field, publishing rigorously peer-reviewed research across the entire spectrum of microbiology. Field Chief Editor Martin G. Klotz at Washington State University is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
